Gilead Sciences (GILD) Net Margin (2009 - 2026)
Gilead Sciences posted quarterly Net Margin of 29.04% for Q1 2026, up 931.0% year-on-year from 2.82% in Q1 2025, and down 8.97% on a QoQ basis from 31.9% in Q4 2025.
Gilead Sciences (GILD) has 18 years of Net Margin data on file, last reported at 29.04% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 931.0% year-over-year to 29.04%; the trailing twelve-month figure through Mar 2026 stood at 32.16% (up 1140.0% YoY), and the FY2025 full-year result was 28.9%, up 2724.0% from the prior year.
- Net Margin for Q1 2026 stood at 29.04%, down from 31.9% in the prior quarter.
- Across five years, Net Margin topped out at 39.28% in Q3 2025 and bottomed at 62.38% in Q1 2024.
- The 5-year median for Net Margin is 22.1% (2022), against an average of 17.43%.
- The widest annual swing landed in 2024, when Net Margin sank 7788 bps; it then jumped 8211 bps in 2025.
- A 5-year view of Net Margin shows it stood at 22.1% in 2022, then dropped by 10 bps to 19.9% in 2023, then climbed by 18 bps to 23.54% in 2024, then soared by 35 bps to 31.9% in 2025, then decreased by 9 bps to 29.04% in 2026.
- The last three Net Margin figures came in at 29.04% (Q1 2026), 31.9% (Q4 2025), and 39.28% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 23.32% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.04% |
| Dec 31, 2025 | 31.90% |
| Sep 30, 2025 | 39.28% |
| Jun 30, 2025 | 27.69% |
| Mar 31, 2025 | 19.72% |
| Dec 31, 2024 | 23.54% |
| Sep 30, 2024 | 16.61% |
| Jun 30, 2024 | 23.22% |
| Mar 31, 2024 | -62.38% |
| Dec 31, 2023 | 19.90% |
| Sep 30, 2023 | 30.80% |
| Jun 30, 2023 | 15.74% |
| Mar 31, 2023 | 15.49% |
| Dec 31, 2022 | 22.10% |
| Sep 30, 2022 | 25.36% |
| Jun 30, 2022 | 18.13% |
| Mar 31, 2022 | 0.18% |
| Dec 31, 2021 | 5.19% |
| Sep 30, 2021 | 34.85% |
| Jun 30, 2021 | 24.29% |
| Mar 31, 2021 | 26.62% |
| Dec 31, 2020 | 20.55% |
| Sep 30, 2020 | 4.97% |
| Jun 30, 2020 | -67.30% |
| Mar 31, 2020 | 25.70% |
| Dec 31, 2019 | 9.80% |
| Sep 30, 2019 | -23.20% |
| Jun 30, 2019 | 30.61% |
| Mar 31, 2019 | 34.61% |
| Dec 31, 2018 | 4.85% |
| Sep 30, 2018 | 34.90% |
| Jun 30, 2018 | 31.11% |
| Mar 31, 2018 | 29.07% |
| Dec 31, 2017 | -62.75% |
| Sep 30, 2017 | 35.37% |
| Jun 30, 2017 | 37.18% |
| Mar 31, 2017 | 34.17% |
| Dec 31, 2016 | 35.83% |
| Sep 30, 2016 | 37.77% |
| Jun 30, 2016 | 37.53% |
| Mar 31, 2016 | 45.77% |
| Dec 31, 2015 | 48.27% |
| Sep 30, 2015 | 48.97% |
| Jun 30, 2015 | 50.34% |
| Mar 31, 2015 | 51.67% |
| Dec 31, 2014 | 41.96% |
| Sep 30, 2014 | 40.16% |
| Jun 30, 2014 | 50.67% |
| Mar 31, 2014 | 38.17% |
| Dec 31, 2013 | 13.19% |
| Sep 30, 2013 | 17.12% |
| Jun 30, 2013 | 18.66% |
| Mar 31, 2013 | 18.86% |
| Dec 31, 2012 | 20.02% |
| Sep 30, 2012 | 21.62% |
| Jun 30, 2012 | 25.98% |
| Mar 31, 2012 | 16.96% |
| Dec 31, 2011 | 24.24% |
| Sep 30, 2011 | 34.76% |
| Jun 30, 2011 | 34.74% |
| Mar 31, 2011 | 33.61% |
| Dec 31, 2010 | 31.34% |
| Sep 30, 2010 | 36.24% |
| Jun 30, 2010 | 36.80% |
| Mar 31, 2010 | 40.85% |
| Dec 31, 2009 | 74.46% |
| Sep 30, 2009 | 37.22% |
| Jun 30, 2009 | 34.55% |
| Mar 31, 2009 | 38.33% |